GeneTex ion channel antibodies
09 August, 2022GeneTex offers a wide selection of antibodies to support ion channel research, with IHC-validated and/or ICC/IF-validated antibodies to facilitate research efforts in this field.
The Native Antigen Company monkeypox antigens
26 July, 2022The Native Antigen Company has moved to develop a series of monkeypox antigens to support research into this disease.
Bio-Rad Laboratories anti-brentuximab vedotin and anti-secukinumab antibodies
14 July, 2022The anti-brentuximab vedotin and anti-secukinumab inhibitory antibodies are available in Fab (fragment antigen-binding) and fully human IgG1 formats with different affinities.
HUABIO phospho-specific recombinant antibodies
07 July, 2022Phospho-specific antibodies can be used to detect the phosphorylated form of the target protein by binding to the site-specific phosphorylated amino acid.
GeneTex vision and retina antibodies
06 July, 2022GeneTex offers a large selection of antibodies for vision and retina research. It offers IHC-validated and/or ICC/IF-validated antibodies.
Absolute Antibody Prometheus antibody humanisation service
17 June, 2022Absolute Antibody has expanded its Prometheus antibody humanisation service to offer humanisation from non-murine origin species, including rabbit antibodies and single-domain camelid nanobodies.
The Native Antigen Company human coronavirus antigens and antibodies
12 May, 2022Native Antigen has rapidly expanded its range of SARS-CoV-2 recombinant antigens and antibodies.
'Mini antibodies' treat mice for inflammation
03 May, 2022Normal antibodies provide additional stimulation to the immune system and can therefore exacerbate inflammation — a property that nanobodies lack.
Merck ZooMAb recombinant antibodies
20 April, 2022ZooMAb antibodies use recombinant technology, which offers an endless and consistent supply while reducing the use of animals in research.
Bio-Rad Laboratories anti-cemiplimab antibodies
15 April, 2022Bio-Rad Laboratories has introduced a range of antibodies that are specific to cemiplimab (Libtayo) and inhibit the binding of the drug to its target, human programmed death receptor-1 (PD-1).
Everest Biotech prostate cancer antibodies
08 April, 2022Everest Biotech's prostate cancer antibodies range includes PSA, AMACR, ERG and essential biomarkers.
GeneTex pyroptosis antibodies
07 April, 2022GeneTex has a range of antibodies for the study of pyroptosis and inflammation biology.
AdipoGen Life Sciences PANoptosome Human Antibodies Starter Set
07 March, 2022AdipoGen Life Sciences' PANoptosome Human Antibodies Starter Set is an all-in-one solution to study the three key modes of programmed cell death using the western blotting application.
LSBio IHC-plus antibodies
04 March, 2022LSBio's IHC-plus antibodies have been tested and identified as being optimal for use in immunohistochemistry (IHC) against FFPE human tissues.
Bio-Rad Laboratories anti-daratumumab antibodies
15 February, 2022Bio-Rad Laboratories has launched a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38.
